natgillin/translations-raw huggingface dataset:
N. arvestades, et dengue kujutab endast ülemaailmset terviseohtu, ja et Aasias esinev teisene dengue vektor Aedes Albopictus on rahvusvahelise kasutatud rehvidega kauplemise tulemusel jõudnud ka Euroopasse ja muudesse piirkondadesse, ning et sellel puudub spetsiaalne ravi, kuid et ühtse vektori juhtimise osas on tehtud edusamme, samal ajal kui vaktsiinide arendamine on olnud aeglane;
N. whereas dengue is a global health concern and Aedes albopictus, a secondary dengue vector in Asia, is now established in Europe and other regions, due to the international used tyre trade; and there is no specific treatment but progress is being made in integrated vector management while the development of vaccines is slow,
O. arvestades, et buruli haavand on esilekerkiv terviseoht, ja et seda saab ravida ainult kahjustust kirurgiliselt eemaldades, millega kaasneb kudede kahjustus või püsiv invaliidsus;
O. whereas Buruli Ulcer is an emerging health threat and can only be treated by surgery to remove the lesion causing loss of tissue or permanent disability,
P. arvestades, et vaimuhaiguste ja epilepsia määr kasvab, ja et sellele pole piisavalt tähelepanu pööratud;
P. whereas the burden of mental illnesses and Epilepsy is growing and neglected,
Q. arvestades, et arengumaade paljudes osades, kus esineb nii väljaränne kui ka siseränne vaesemates piirkondades, on tervishoiutöötajatest tõsine puudus;
Q. whereas there is a grave shortage of health workers in many parts of the developing world, with migration both from and within poorer regions,
R. arvestades, et meditsiiniseadmete korduskasutamine põhjustas 2000. aastal hinnanguliselt 260 000 uut HIV/AIDSi juhtu, 2 miljonit C-hepatiiti nakatumist ja 21 miljonit B-hepatiiti nakatumist;
R. whereas re-used medical devices led to an estimated 260,000 new cases of HIV/AIDS, 2 million hepatitis C infections and 21 million hepatitis B infections in 2000,
S. arvestades, et tubakatoodete tarvitamine põhjustab aastas 5 miljonit surma, ja et see arv võib 2020. aastaks kahekordistuda, kusjuures enamik surmajuhtumitest esineb arengumaades;
S. whereas 5 million deaths worldwide are caused annually by tobacco use and this could double by 2020 with the majority occurring in developing countries,
T. arvestades kroonilist investeeringute puudust vaesusega seotud haiguste ravimite osas tehtavatesse rahvusvahelistesse ja piirkondlikesse uuringutesse;
T. whereas there is a chronic lack of investment in international and regional research in drugs for poverty-related diseases,
U. arvestades, et hinnanguliselt on vähem kui 10% maailma biomeditsiiniliste teadusuuringute rahalistest vahenditest määratud tegelemiseks probleemidega, mis moodustavad 90% maailma haiguste määrast, ning et kõikidest 1999.–2000. aastal tähelepanuta jäetud haiguste jaoks väljatöötamisel olevatest ravimistest oli kliinilises arenduses 18 uurimis- ja arendustegevuse projekti võrreldes 2100 ühendiga kõikide ülejäänud haiguste jaoks, ning et tähelepanuta jäänud haiguste osas tehtava kliinilise arenduse keskmine aeg on muude haigustega võrreldes umbes kolme ja poole aasta võrra pikem;
U. whereas it is estimated that less than 10% of the world’s biomedical research funds are dedicated to addressing problems that are responsible for 90% of the world’s burden of disease and that, of all drugs in development for all neglected diseases in 1999-2000, 18 R&D projects were in clinical development, compared to 2,100 compounds for all other diseases and the mean time for clinical development for neglected diseases is about three and a half years more than for other conditions,
V. arvestades, et on tehtud teaduslikke edusamme, sealhulgas ka malaariat, leišmaniaasi ja aafrika trüpanosomiaasi põhjustavate parasiitide genoomi sekventeerimisel, kuid et edusamme ei ole uute toodete loomiseks kasutatud;
V. whereas scientific advances have been made, including the genome sequencing of parasites causing malaria, leishmaniasis and HAT, but these are not being translated into new products,
W. arvestades, et WHO eelkvalifitseerimise projekt ( WHO Prequalification Project ) on uute hädavajalike ravimite hindamise ja hankimise oluline võrgustik;
W. whereas the WHO Prequalification Project is an important network for assessing and procuring new essential medicines,
X. arvestades, et igal aastal sureb hinnanguliselt 1,5 miljonit alla viieaastast last vaktsiinidega ennetatavatesse haigustesse;
X. whereas yearly an estimated one and a half million children under five die from vaccine preventable diseases,
Y. arvestades, et vaid üks ravimiettevõte on registreerinud kättesaadavaid soodushindadega ravimeid nõukogu 26. mai 2003. aasta määruse (EÜ) nr 935/2003 alusel, mis käsitleb teatud peamiste ravimite Euroopa Liidu riikidesse toomisega seotud kaubandushäirete vältimist
Y. whereas only one pharmaceutical company has registered medicines available at reduced cost under Council Regulation (EC) No 953/2003 of 26 May 2003 to avoid trade diversion into the European Union of certain key medicines
ELT L 135, 3.6.2003, lk 5.
OJ L 135, 3.6.2003, p.
Z. arvestades, et kõik WTO liikmesriigid, eriti geneeriliste ravimite tootjamaad, oleksid pidanud integreerima intellektuaalomandi õiguste kaubandusaspektide lepingu oma siseriiklikesse õigusaktidesse,
Z. whereas all WTO Member States should have integrated the TRIPS agreement on intellectual property rights into their national legislation, particularly States which produce generic medicines,
2. nõuab tungivalt, et komisjon viiks HIV/AIDSi, tuberkuloosi ja malaaria vastu võitlemise uue tegevusprogrammi poliitilised ettepanekud ellu, tagades asjakohased kavandamisotsused ja piisavad eelarveassigneeringud;
Urges the Commission to translate the policy proposals of the new Programme for Action to confront HIV/AIDS, TB and Malaria into concrete action by ensuring appropriate programming decisions and sufficient budget allocations;
2005/0033 (COD). , et reageerida ühiselt erinevat päritolu hädaolukordadele tõhusal ja koordineeritud viisil;
2005/0033 (COD) in order to provide a common response to emergency situations of different origin in an efficient and coordinated way;
10. rõhutab, et joogiveele ja toidule juurdepääs on rahva hea tervise oluline tingimus; nõuab seega tungivalt tervise transversaalset mõõdet ja elutingimuste parendamist, mis aitab kaasa elulootuse suurendamisele;
Stresses that access to drinking water and food are essential conditions for healthy populations; insists therefore on the cross dimension of health and the improvement of living conditions which contributes to increasing life expectancy;
13. nõuab, et komisjoni tegevusprogrammis sätestatud inimressursse käsitlevas dokumendis sisalduksid ka ettepanekud kiireloomulise tegevuse kohta arengumaade tervishoiutöötajate vähenemise peatamiseks, näiteks parem koolitus, paremad karjäärivõimalused, parem töötasu, maksusoodustused, turvalised töötingimused, koostöö haiguspõhiste algatustega, mestimiskokkulepped, vabatahtlik toetus ning parima tava ja tehnilise toetuse levitamine;
Calls for the policy document on human resources provided for in the Commission's Programme for Action also to include proposals for urgent action to reverse the loss of health workers from developing countries such as better training, career opportunities, remuneration, retention incentives, safe working conditions, cooperation with disease-specific initiatives, twinning arrangements, voluntary support and the spread of best practice and technical support;
Eurobaromeetri eriuuring 222 suhtumise kohta arenguabisse, veebruar 2005. ;
Special Eurobarometer 222, Attitudes towards Development Aid, February 2005. ;
21. rõhutab riigijuhtimise ja aruandekohustuse tähtsust ning kutsub komisjoni üles tagama asjassepuutuvate kogukondade ja kodanikuühiskonna tähenduslik kaasamine nimetatud protsessi, et tagada marginaliseeritud kogukondade murede ja kogemuste kajastamine tegevusraamistikes;
Stresses the importance of country leadership and accountability and calls on the Commission to ensure that affected communities and civil society are meaningfully involved in this process to ensure that Action Frameworks reflect the concerns and experiences of marginalised communities;
28. nõuab vaesuse vähendamise poliitikas ning HIV/AIDSist ja muudest haigustest mõjutatud perekondade toetamisel eakate inimeste ning orbude ja muude ohustatud laste arvesse võtmist ning nende kaasamist ja osalemist programmide kavandamises ja rakendamises;
Calls for older people, orphans and other vulnerable children to be taken into account in policies for poverty reduction and support for families affected by HIV/AIDS and other diseases, and for their involvement and participation in the design and implementation of programmes;
48. julgustab komisjoni nüüdsest peale uurima viise konkreetsete sammude astumiseks seoses olemasolevate ja kavandatavate temaatiliste eelarveridade pandlikkusega ning menetluste lihtsustamisega, et parendada ühenduse poliitika, teenuste ja programmide sünergiat ja kooskõla võitluses kolme asjassepuutuva haiguse vastu;
Encourages the Commission to examine as of now ways of implementing the specific steps to be taken with regard to the flexibility of current and planned thematic budget lines and also to simplify procedures in order to improve the synergy and consistency of Community policies, services and programmes in the fight against the three diseases;
51. nõuab arengumaades praktiseerivate meditsiinitöötajate töötingimuste parandamist, sobiva meditsiinitehnika hankimist ja tehnoloogiasiiret; nõuab Euroopa arstide arenguriikidesse ja vastupidi toimuva siirdumise alaste vahetusprogrammide arvu suurenemist;
Calls for the improvement of working conditions for medical staff practising in developing countries, the provision of suitable medical equipment and transfer of technology; calls for an increase in exchange programmes of doctors from Europe to developing countries and vice versa;
(I ja IV faas). ;
(Phase I and IV). ;
(Stop it at the start; it's late for medicine to be prepared when disease has grown strong through long delays).
(Stop it at the start; it's late for medicine to be prepared when disease has grown strong through long delays).
2005 has seen a new health threat on our agenda: Marburg emerged in Angola.
2005 has seen a new health threat on our agenda: Marburg emerged in Angola.
This deadly haemorrhagic disease has a mortality rate of over 90%.
This deadly haemorrhagic disease has a mortality rate of over 90%.
ECHO has swiftly supported Médecins Sans Frontières in providing not just powerful antibiotics and intravenous fluids, but water purification systems and disposable protective gear.
ECHO has swiftly supported Médecins Sans Frontières in providing not just powerful antibiotics and intravenous fluids, but water purification systems and disposable protective gear.
Just one example of the need for vigilance, prevention and rapid response, just one reason why we must never cherry pick in our battle against disease.
Just one example of the need for vigilance, prevention and rapid response, just one reason why we must never cherry pick in our battle against disease.
We must continue to tackle the Big Three of AIDS, Malaria and Tuberculosis - which are still not under control and are still spreading to new regions - but as many or more people die, become chronically ill or live with disabilities caused by diseases the world neglects.
We must continue to tackle the Big Three of AIDS, Malaria and Tuberculosis - which are still not under control and are still spreading to new regions - but as many or more people die, become chronically ill or live with disabilities caused by diseases the world neglects.
It is time to end that poverty of fatalism; it is time to bring neglected diseases in from the cold and to bring real hope to those who live with and too often die from them.
It is time to end that poverty of fatalism; it is time to bring neglected diseases in from the cold and to bring real hope to those who live with and too often die from them.
There are emerging health threats from new diseases such as Avian Flu and Ebola, which pose a growing risk to EU citizens as a result of the increase in travel and population mobility.
There are emerging health threats from new diseases such as Avian Flu and Ebola, which pose a growing risk to EU citizens as a result of the increase in travel and population mobility.
It is possible that some of these diseases will increase in frequency in the western world as a result of global warming.
It is possible that some of these diseases will increase in frequency in the western world as a result of global warming.
Meanwhile, old infectious diseases are resurgent, notably TB, increasingly in multi-drug resistant strains.
Meanwhile, old infectious diseases are resurgent, notably TB, increasingly in multi-drug resistant strains.
The fight against disease everywhere is in everybody’s health and indeed security interests.
The fight against disease everywhere is in everybody’s health and indeed security interests.
Health research and development (R&D) can yield rapid results.
Health research and development (R&D) can yield rapid results.
The outbreak of Severe Acute Respiratory Syndrome (SARS) in 2003 led to unprecedented international cooperation to sequence the virus, and through successful public and private cooperation, to develop and deploy a diagnostic kit.
The outbreak of Severe Acute Respiratory Syndrome (SARS) in 2003 led to unprecedented international cooperation to sequence the virus, and through successful public and private cooperation, to develop and deploy a diagnostic kit.
SARS also made communicable disease a political priority, leading to the establishment of the European Centre for Disease Prevention and Control.
SARS also made communicable disease a political priority, leading to the establishment of the European Centre for Disease Prevention and Control.
We need the same dynamic approach to deal with other major global diseases.
We need the same dynamic approach to deal with other major global diseases.
Only a very few new drugs and vaccines have been developed to deal with the “most neglected diseases” - often parasitic diseases such as Leishmaniasis, Sleeping Sickness or Onchocerciasis, and Dengue, Trachoma and infectious diarrhoeal diseases.
Only a very few new drugs and vaccines have been developed to deal with the “most neglected diseases” - often parasitic diseases such as Leishmaniasis, Sleeping Sickness or Onchocerciasis, and Dengue, Trachoma and infectious diarrhoeal diseases.
Patients suffering from these illnesses are given archaic drugs, some of which are highly toxic, ineffective or difficult to administer.
Patients suffering from these illnesses are given archaic drugs, some of which are highly toxic, ineffective or difficult to administer.
Urgent action is needed to develop new drugs, tests and vaccines that are adapted to developing countries’ needs, and to make them available at affordable prices.
Urgent action is needed to develop new drugs, tests and vaccines that are adapted to developing countries’ needs, and to make them available at affordable prices.
Less than 1% of the 1,393 new drugs placed on the market between 1975 and 1999 were developed for infectious, tropical diseases.
Less than 1% of the 1,393 new drugs placed on the market between 1975 and 1999 were developed for infectious, tropical diseases.
Since then the situation has remained virtually unchanged, although a handful of organisations are now working to change it.
Since then the situation has remained virtually unchanged, although a handful of organisations are now working to change it.
There already exists the scientific knowledge that could contribute to the development of new treatments.
There already exists the scientific knowledge that could contribute to the development of new treatments.
Because of the lack of a viable commercial market, they need direct support to ensure that the R&D is carried out to find new diagnostic tests and treatments.
Because of the lack of a viable commercial market, they need direct support to ensure that the R&D is carried out to find new diagnostic tests and treatments.
To our shame, “Neglected Diseases” have not received the attention they deserve from EU actions.
To our shame, “Neglected Diseases” have not received the attention they deserve from EU actions.
The European Parliament, in its report of 12 July 2001
The European Parliament, in its report of 12 July 2001
( A5-0263/2001 ). specifically requested the Commission “to take the initiative for a proposal for neglected diseases (such as trypanosomiasis, filariasis, bilharzia and ebola); this proposal should provide incentive for the development of drugs and vaccines destined to combat poverty-related diseases for which there is a limited market”.
( A5-0263/2001 ). specifically requested the Commission “to take the initiative for a proposal for neglected diseases (such as trypanosomiasis, filariasis, bilharzia and ebola); this proposal should provide incentive for the development of drugs and vaccines destined to combat poverty-related diseases for which there is a limited market”.
Then, its report of 10 December 2003
Then, its report of 10 December 2003
( A5-0474/2003 ). on the update of the EC Programme for Action said “no research is currently being carried out into the most neglected diseases which mainly affect developing countries ” and that “there is a chronic shortage of investment in research and development in poverty-related diseases and in R&D in the developing countries themselves to obtain the medicines which meet the needs of those countries”.
( A5-0474/2003 ). on the update of the EC Programme for Action said “no research is currently being carried out into the most neglected diseases which mainly affect developing countries ” and that “there is a chronic shortage of investment in research and development in poverty-related diseases and in R&D in the developing countries themselves to obtain the medicines which meet the needs of those countries”.
To get drugs for neglected diseases on the market, the Commission should support integrated research projects involving the complete process of identification of likely candidate chemicals through to the most effective and least toxic being put on the market.
To get drugs for neglected diseases on the market, the Commission should support integrated research projects involving the complete process of identification of likely candidate chemicals through to the most effective and least toxic being put on the market.
This will involve screening potential chemicals which are active against these diseases, selection of those with the most potential, carrying out pre-clinical testing on them, and based on these results, developing and carrying out clinical trials on the most promising drugs.
This will involve screening potential chemicals which are active against these diseases, selection of those with the most potential, carrying out pre-clinical testing on them, and based on these results, developing and carrying out clinical trials on the most promising drugs.
The emphasis on “translational research” to bridge the gaps between basic research and useful applications in the Seventh Research Framework Programme is good news - but this should explicitly include neglected diseases most in need of such research.
The emphasis on “translational research” to bridge the gaps between basic research and useful applications in the Seventh Research Framework Programme is good news - but this should explicitly include neglected diseases most in need of such research.
In addition, the activities of the EDCTP should be expanded to include other neglected diseases as well as other phases of clinical development.
In addition, the activities of the EDCTP should be expanded to include other neglected diseases as well as other phases of clinical development.
DNDi has estimated that over the next ten years a minimum of €250 million will be needed to put on the market six or seven medicines that are effective against Trypanosomiasis, Chagas Disease, and Leishmaniasis, and to have a balanced portfolio for other key medicines at various stages of development.
DNDi has estimated that over the next ten years a minimum of €250 million will be needed to put on the market six or seven medicines that are effective against Trypanosomiasis, Chagas Disease, and Leishmaniasis, and to have a balanced portfolio for other key medicines at various stages of development.
Health systems in many developing countries are starved of resources.
Health systems in many developing countries are starved of resources.
The countries themselves will need to mobilise increased investment for better health outcomes, and initiatives to commit more money from national budgets to health are welcome.
The countries themselves will need to mobilise increased investment for better health outcomes, and initiatives to commit more money from national budgets to health are welcome.
Yet the international community will need to complement country level public and private investments with long-term financial support; many countries will require capacity building and technical support, including training of health workers at the local level.
Yet the international community will need to complement country level public and private investments with long-term financial support; many countries will require capacity building and technical support, including training of health workers at the local level.
To this end, the European Parliament has consistently called for adequate, predictable and additional funding and for 35% of development aid to be allocated to health and education.
To this end, the European Parliament has consistently called for adequate, predictable and additional funding and for 35% of development aid to be allocated to health and education.
Nor should it be forgotten that millions of people throughout the world suffer from mental and neurological disease.
Nor should it be forgotten that millions of people throughout the world suffer from mental and neurological disease.
Although effective treatments exist for many of these diseases, most of the middle and low-income countries devote less than 1% of their health expenditure to mental and neurological health.
Although effective treatments exist for many of these diseases, most of the middle and low-income countries devote less than 1% of their health expenditure to mental and neurological health.
Developing countries have inadequate access to affordable services and drugs.
Developing countries have inadequate access to affordable services and drugs.
The reasons are complex and include the effects of international and national pricing policies, tariffs, taxation and the implementation of intellectual property rights agreements.
The reasons are complex and include the effects of international and national pricing policies, tariffs, taxation and the implementation of intellectual property rights agreements.
Options to further improve access and affordability include the exploration of the use of differential or tiered pricing, voluntary licensing agreements, technology transfer and an increase in local capacity for production.
Options to further improve access and affordability include the exploration of the use of differential or tiered pricing, voluntary licensing agreements, technology transfer and an increase in local capacity for production.
Diseases which merit attention
Diseases which merit attention
Globally 2.2 billion people are at risk of Malaria.
Globally 2.2 billion people are at risk of Malaria.
Plasmodium falciparum is the most deadly form of Malaria of which there were over 500 million cases in 2002.
Plasmodium falciparum is the most deadly form of Malaria of which there were over 500 million cases in 2002.
Most common in sub-Saharan Africa, it causes extremely high mortality, mostly in children.
Most common in sub-Saharan Africa, it causes extremely high mortality, mostly in children.
Pregnant women and unborn children are particularly vulnerable.
Pregnant women and unborn children are particularly vulnerable.